Francesco Agustoni

Pavia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment.

Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment.

Journal: Clinical colorectal cancer

Published: March 18, 2026

Thyroid toxicity in lung cancer patients treated with immune-checkpoint inhibitors: a single-center retrospective analysis.

Thyroid toxicity in lung cancer patients treated with immune-checkpoint inhibitors: a single-center retrospective analysis.

Journal: Frontiers in immunology

Published: November 30, 2025

Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial).

Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial).

Journal: JNCI cancer spectrum

Published: November 18, 2025

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 13, 2025

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 16, 2025

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Journal: Journal for immunotherapy of cancer

Published: July 31, 2025

Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients.

Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients.

Journal: Tumori

Published: July 10, 2025

A non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination.

A non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination.

Journal: Frontiers in oncology

Published: June 06, 2025

Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study.

Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study.

Journal: ESMO open

Published: May 02, 2025

Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features.

Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features.

Journal: Frontiers in oncology

Published: April 29, 2025

Nutritional status, immunonutrition, and gut microbiome: a coming of age for immunotherapy?

Nutritional status, immunonutrition, and gut microbiome: a coming of age for immunotherapy?

Journal: Frontiers in immunology

Published: April 15, 2025

Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts.

Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts.

Journal: Frontiers in immunology

Published: March 03, 2025

Showing 1-12 of 73

Last Updated: 09/26/2026